Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections

IntroductionThe effect of tixagevimab/cilgavimab (Evusheld™; AstraZeneca, UK) should be evaluated in the context of concurrent outbreak situations.MethodsFor serologic investigation of tixagevimab/cilgavimab during the BA.5 outbreak period, sera of immunocompromised (IC) hosts sampled before and one...

Full description

Bibliographic Details
Main Authors: Jinyoung Yang, Gunho Won, Jin Yang Baek, Young Ho Lee, Haein Kim, Kyungmin Huh, Sun Young Cho, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck, Kyo Won Lee, Jae Berm Park, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim, Min Su Yim, Kwangwook Kim, Seokhwan Hyeon, Byung Chul Kim, Yoo-kyung Lee, Jae-Hoon Ko
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
COVID-19
SARS-CoV-2
Evusheld
neutralizing antibody
BA.5 variant
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1139980/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1139980/full

Similar Items